Comparison of Three Roche Hepatitis B Virus Viral Load Assay Formats
Authors:
Open Access
- 1 July 2012
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 50 (7) , 2337-2342
Abstract
Two FDA-approved ( in vitro diagnostic [IVD]) hepatitis B virus (HBV) viral load assays, the manual Cobas TaqMan HBV Test for use with the High Pure System (HP) and the automated Cobas AmpliPrep/Cobas TaqMan HBV Test v2.0 (CAP/CTM), were compared to a modified (not FDA-approved) version of the HP assay by automating the DNA extraction using the Total Nucleic Acid Isolation (TNAI) kit on the Cobas AmpliPrep. On average, CAP/CTM measurements were 0.08 log IU/ml higher than HP results ( n = 206), and TNAI results were 0.17 log IU/ml higher than HP results ( n = 166). The limit of detection (LOD), as determined by probit analysis using dilutions of the 2nd HBV international standard, was 10.2 IU/ml for CAP/CTM. The data sets for HP and TNAI were insufficient for probit analysis; however, there was 100% detection at ≥5 or ≥10 IU/ml for TNAI and HP, respectively. Linearity was demonstrated between 60 and 2,000,000 IU/ml, with slopes between 0.95 and 0.99 and R 2 values of >0.99 for all assays. Total precision (log percent coefficient of variance [CV]) was between 0.8% and 2.1% at 4.3 log IU/ml and between 1.4% and 4.9% at 2.3 log IU/ml. Correlation of samples, reproducibility, linearity, and LOD were acceptable and similar in all assays. The CAP/CTM assay and, to a lesser extent, the TNAI assay reduced hands-on time due to automation. There were no instances of contamination detected in negative samples during the course of the study, despite testing several samples up to 9.6 log IU/ml. The incidence of false-positive negative controls in HP and CAP/CTM clinical testing was <0.5% over 6 to 7 months of testing.Keywords
This publication has 11 references indexed in Scilit:
- Multilaboratory Evaluation of Real-Time PCR Tests for Hepatitis B Virus DNA QuantificationJournal of Clinical Microbiology, 2011
- Treatment of chronic hepatitis B: Evolution over two decadesJournal of Gastroenterology and Hepatology, 2011
- Detection and quantitation of HBV DNA in miniaturized samples: Multi centre study to evaluate the performance of the COBAS® AmpliPrep/COBAS® TaqMan® hepatitis B virus (HBV) test v2.0 by the use of plasma or serum specimensJournal of Virological Methods, 2010
- Review of Hepatitis B TherapeuticsClinical Infectious Diseases, 2010
- Performance of Version 2.0 of the Cobas AmpliPrep/Cobas TaqMan Real-Time PCR Assay for Hepatitis B Virus DNA QuantificationJournal of Clinical Microbiology, 2010
- Hepatitis B virus (HBV) genotype determination by the COBAS® AmpliPrep/COBAS® TaqMan® HBV Test, v2.0 in serum and plasma matricesJournal of Clinical Virology, 2009
- Hepatitis B Virus InfectionNew England Journal of Medicine, 2008
- Fully automated quantitation of Hepatitis B virus (HBV) DNA in human plasma by the COBAS® AmpliPrep/COBAS® TaqMan® System☆, ☆☆Journal of Clinical Virology, 2006
- Evaluation of the COBAS AmpliPrep-Total Nucleic Acid Isolation-COBAS TaqMan Hepatitis B Virus (HBV) Quantitative Test and Comparison to the VERSANT HBV DNA 3.0 AssayJournal of Clinical Microbiology, 2006
- Real time TaqMan PCR detection and quantitation of HBV genotypes A–G with the use of an internal quantitation standardJournal of Clinical Virology, 2004